Article Text

other Versions

PDF
Early and long-lasting protection from arthritis in TNFα transgenic mice vaccinated against TNFα
  1. Laure Delavallée (delavallee{at}smbh.univ-paris13.fr)
  1. Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, Université Paris13, France
    1. Hélène Le Buanec (helene.le.buanec{at}ulb.ac.be)
    1. Neovacs, Incorporated and Université Pierre et Marie Curie, France
      1. Natacha Bessis (n.bessis{at}smbh.univ-paris13.fr)
      1. Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, Université Paris13, France
        1. Eric Assier (e.assier{at}smbh.univ-paris13.fr)
        1. Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, Université Paris13, France
          1. Anne Denys (a.denys{at}smbh.univ-paris13.fr)
          1. Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, Université Paris13, France
            1. Bernard Bizzini (bdrouet{at}neovacs.com)
            1. Neovacs, Incorporated and Université Pierre et Marie Curie, France
              1. Daniel Zagury (dzagury{at}neovacs.com)
              1. Neovacs, Incorporated and Université Pierre et Marie Curie, France
                1. Marie-Christophe Boissier (marie-christophe.boissier{at}avc.aphp.fr)
                1. Institut National de la Santé et de la Recherche Médicale (INSERM) ERI18, Université Paris13, France

                  Abstract

                  Objective: To evaluate the effect in mice with arthritis of active anti-TNFα immunotherapy based on a keyhole limpet hemocyanin-human TNFα heterocomplex (hTNFα kinoid or TNFK) adjuvanted in incomplete Freund adjuvant. Immunotherapy was evaluated also with methotrexate.

                  Methods: Human TNFα-transgenic mice received hTNFα kinoid with or without methotrexate. Follow-up ranged from 6 weeks (short-term) to 17 weeks (long-term). Arthritis was evaluated clinically and histologically. Monitoring included titration of anti-hTNFα antibodies by ELISA and neutralization assay.

                  Results: Vaccination with TNFK was associated with rapid-onset, long-lasting protection. Long-term results showed significantly milder arthritis in vaccinated animals than in control animals at the peak of the disease. Vaccination was followed by resolution of the clinical evidence of arthritis, contrasting with severe progressive arthritis in the control group. Histological improvements with decreased inflammation and destruction were noted in all immunized groups, even after the shortest follow-up (6 weeks). High titers of neutralizing anti-hTNFα antibodies were detected as early as the fifth post-immunization week and persisted over time. Methotrexate given concomitantly with the vaccine did not influence either the effect on arthritis or the anti-hTNFα antibody titers.

                  Conclusion: Anti-cytokine induction of autoimmune protection against chronic hTNFα overproduction is an efficient alternative to TNFα blockade in experimental arthritis and can be achieved using a TNFK vaccine.

                  • anti-TNF alpha
                  • hTNFalpha transgenic mice
                  • rheumatoid arthritis

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.